Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
United Press International - October 11, 2007
UPTON, N.Y., Oct. 11 (UPI) -- U.S. scientists have developed peptides significantly more effective at blocking the human immunodeficiency virus from entering cells.
Based in part on protein structures determined at the National Synchrotron Light Source at the U.S. Department of Energy's Brookhaven National Laboratory, researchers said their peptides are sufficiently potent to begin pre-clinical studies as a potential new class of agents for the prevention and treatment of HIV and AIDS.
"Our 'D-peptides' offer several potential therapeutic advantages over existing peptide entry inhibitors, which are costly, require high dose injections, and suffer from the emergence of drug-resistance," said University of Utah biochemist Michael Kay, lead author of the study. "In contrast, our D-peptides resist degradation, so they have the potential to be administered by mouth and last longer in the bloodstream. Since these inhibitors have a unique inhibitory mechanism, they should work well in combination with existing HIV inhibitors."
The work appears in the early online edition of the Proceedings of the National Academy of Sciences.
For additional information, please go to: http://www.bnl.gov/bnlweb/pubaf/pr/PR_display.asp?prID=07-101
071011
UPI071005
Copyright © 2007 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .